PDE concept for controlling cleaning agent residues in pharmaceuticals- A critical analysis.

Builders Cleaning agents (CAs) Cross-contamination Mode of action reasoning Oxidizers Permitted daily exposure (PDE) Read-across Residues Surfactants pH modifiers

Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 16 07 2021
revised: 05 11 2021
accepted: 02 12 2021
pubmed: 11 12 2021
medline: 28 1 2022
entrez: 10 12 2021
Statut: ppublish

Résumé

Cleaning agents (CAs) are used in multipurpose facilities to control carryover contamination of active pharmaceutical ingredients (APIs) to scientifically justified limits. While this is often done with the PDE methodology used for API impurities, it is unclear if it is justifiable and necessary for cleaning agents, which generally represent a comparatively lower health risk. Comparing calculated oral PDE values for CA ingredients (CAIs) from four companies with PDEs of a selected number of small-molecule APIs showed that the toxicity of CAIs is several orders of magnitude lower. Furthermore, a critical review of the toxicity and everyday exposure to the general population of the main CAIs functional groups showed that the expected health risks are generally negligible. This is particularly true if the associated mode of actions cause local toxicity that is usually irrelevant at the concentration of potential residue carryover. This work points towards alternative approaches to the PDE concept to control CAIs' contamination and provides some guidance on grouping and identifying compounds with lower health risks based on exposure and mode of action reasoning. In addition, this work supports the concept that limit values should only be set for CAIs of toxicological concern.

Identifiants

pubmed: 34890761
pii: S0273-2300(21)00236-1
doi: 10.1016/j.yrtph.2021.105095
pii:
doi:

Substances chimiques

Detergents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105095

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

S Araya (S)

Lonza, Switzerland. Electronic address: selene.araya@lonza.com.

T Pfister (T)

F. Hoffmann-La Roche, Switzerland.

K Gromek (K)

GlaxoSmithKline, United Kingdom.

W Hawkins (W)

SafeBridge Europe Ltd., United Kingdom.

S T Thomsen (ST)

Novo Nordisk, Denmark.

N Clemann (N)

F. Hoffmann-La Roche, Switzerland.

S Faltermann (S)

F. Hoffmann-La Roche, Switzerland.

L Wiesner (L)

Lonza, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH